Zogenix (NASDAQ:ZGNX) announces that The Lancet has published the results of its Phase 3 trial for Fintepla in children and young adults with Dravet syndrome, a rare, catastrophic form of epilepsy.
The primary endpoint was the change in mean monthly frequency of convulsive seizures. Patients receiving a dose of 0.7 mg/kg/day achieved a 62.3% greater reduction compared to placebo.
The group treated at 0.2 mg/kg/day compared to placebo, the secondary endpoint, showed a 32.4% grater reduction in frequency.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.